Evolutionary age correlates with range size across plants and animals.

More than 40 thousand species of plants and animals are facing extinction worldwide. Range size is one of the strongest determinants of extinction risk, but the causes underlying the wide variation in natural range sizes remain poorly understood. Here, we investigate how species' age is related to present-day range size for over 26,000 species of mammals, birds, reptiles, amphibians, reef fishes, and plants.

Temporal trends of a cellular host response test for sepsis and a comparison with selected biomarkers of inflammation and infection.

Sepsis, a condition characterized by immune dysregulation, is the leading cause of in-hospital mortality and requires rapid treatment. Assessing immune dysregulation has been challenging. The IntelliSep Index (ISI), a novel biomarker which leverages microfluidic deformability cytometry to assess immune activation, has been evaluated as a test for Emergency Department use but it is unclear how the signal evolves as patient condition evolves.

Confidence Intervals for Adaptive Trial Designs II: Case Study and Practical Guidance.

In adaptive clinical trials, the conventional confidence interval (CI) for a treatment effect is prone to undesirable properties such as undercoverage and potential inconsistency with the final hypothesis testing decision. Accordingly, as is stated in recent regulatory guidance on adaptive designs, there is the need for caution in the interpretation of CIs constructed during and after an adaptive clinical trial. However, it may be unclear which of the available CIs in the literature are preferable.

Confidence Intervals for Adaptive Trial Designs I: A Methodological Review.

Regulatory guidance notes the need for caution in the interpretation of confidence intervals (CIs) constructed during and after an adaptive clinical trial. Conventional CIs of the treatment effects are prone to undercoverage (as well as other undesirable properties) in many adaptive designs (ADs) because they do not take into account the potential and realized trial adaptations. This paper is the first in a two-part series that explores CIs for adaptive trials.